These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 30866997)
1. clonealign: statistical integration of independent single-cell RNA and DNA sequencing data from human cancers. Campbell KR; Steif A; Laks E; Zahn H; Lai D; McPherson A; Farahani H; Kabeer F; O'Flanagan C; Biele J; Brimhall J; Wang B; Walters P; ; Bouchard-Côté A; Aparicio S; Shah SP Genome Biol; 2019 Mar; 20(1):54. PubMed ID: 30866997 [TBL] [Abstract][Full Text] [Related]
2. Clonal genotype and population structure inference from single-cell tumor sequencing. Roth A; McPherson A; Laks E; Biele J; Yap D; Wan A; Smith MA; Nielsen CB; McAlpine JN; Aparicio S; Bouchard-Côté A; Shah SP Nat Methods; 2016 Jul; 13(7):573-6. PubMed ID: 27183439 [TBL] [Abstract][Full Text] [Related]
3. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. McPherson A; Roth A; Laks E; Masud T; Bashashati A; Zhang AW; Ha G; Biele J; Yap D; Wan A; Prentice LM; Khattra J; Smith MA; Nielsen CB; Mullaly SC; Kalloger S; Karnezis A; Shumansky K; Siu C; Rosner J; Chan HL; Ho J; Melnyk N; Senz J; Yang W; Moore R; Mungall AJ; Marra MA; Bouchard-Côté A; Gilks CB; Huntsman DG; McAlpine JN; Aparicio S; Shah SP Nat Genet; 2016 Jul; 48(7):758-67. PubMed ID: 27182968 [TBL] [Abstract][Full Text] [Related]
4. The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer. El-Arabey AA; Abdalla M Hum Cell; 2022 Jul; 35(4):1298-1300. PubMed ID: 35459984 [No Abstract] [Full Text] [Related]
5. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626 [TBL] [Abstract][Full Text] [Related]
6. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Shao H; Mohamed EM; Xu GG; Waters M; Jing K; Ma Y; Zhang Y; Spiegel S; Idowu MO; Fang X Oncotarget; 2016 Jan; 7(4):3832-46. PubMed ID: 26716645 [TBL] [Abstract][Full Text] [Related]
8. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360 [TBL] [Abstract][Full Text] [Related]
9. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences. Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK Cells; 2021 Dec; 10(12):. PubMed ID: 34944094 [TBL] [Abstract][Full Text] [Related]
11. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing. Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862 [TBL] [Abstract][Full Text] [Related]
12. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer. Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233 [TBL] [Abstract][Full Text] [Related]
15. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related]
16. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645 [TBL] [Abstract][Full Text] [Related]
17. Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities. Li L; Bai H; Yang J; Cao D; Shen K Oncotarget; 2017 Feb; 8(9):15136-15148. PubMed ID: 28122348 [TBL] [Abstract][Full Text] [Related]
18. A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. Bai Y; Li LD; Li J; Chen RF; Yu HL; Sun HF; Wang JY; Lu X Int J Oncol; 2020 Jan; 56(1):301-314. PubMed ID: 31746425 [TBL] [Abstract][Full Text] [Related]
19. Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers. Chudasama D; Bo V; Hall M; Anikin V; Jeyaneethi J; Gregory J; Pados G; Tucker A; Harvey A; Pink R; Karteris E Carcinogenesis; 2018 Mar; 39(3):407-417. PubMed ID: 29126163 [TBL] [Abstract][Full Text] [Related]
20. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Mehner C; Hockla A; Miller E; Ran S; Radisky DC; Radisky ES Oncotarget; 2014 May; 5(9):2736-49. PubMed ID: 24811362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]